Skip to main content

Table 2 Thyroid hormone levels of PWS in the different groups

From: Thyroid function in children with Prader-Willi syndrome in Southern China: a single-center retrospective case series

 

FT4(pmol/L)

TSH(mIU/L)

C-HT(columna)

C-HT(rowb)

Age

 < 0.08y (n = 11)

18.34 ± 3.30 (12.54–23.81)

Ref.(12.00–29.34)

3.19 ± 1.46 (1.36–6.42)

Ref.(0.47–10.00)

0

0

0.08y-0.99y (n = 46)

14.17 ± 2.75 (8.58–19.14)

Ref.(13.17–22.33)

3.00 ± 2.09 (0.02–9.44)

Ref.(0.36–7.63)

18(38.3%)

18(39.1%)

1y-2.99y (n = 23)

15.38 ± 3.47 (9.19–23.01)

Ref.(14.45–22.74)

2.77 ± 1.85 (0.41–8.39)

Ref.(0.38–7.31)

12(25.5%)

12(52.2%)

3y-5.99y (n = 26)

16.71 ± 2.66 (13.10–21.18)

Ref.(15.49–22.38)

2.61 ± 0.83 (1.23–4.22)

Ref.(0.65–7.18)

12(25.5%)

12(46.2%)

6y-8.99y (n = 12)

16.52 ± 3.24 (12.06–21.75)

Ref.(14.42–22.22)

2.47 ± 1.03 (0.96–4.03)

Ref.(0.79–6.06)

4(8.5%)

4(33.3%)

9y-11.99y (n = 8)

17.40 ± 4.81 (11.28–27.61)

Ref.(13.44–23.61)

2.44 ± 1.25 (0.99–4.54)

Ref.(0.91–4.63)

1(2.1%)

1(12.5%)

 > 12y (n = 4)

17.85 ± 4.50 (14.43–23.96)

Ref.(11.5–22.7)

1.87 ± 0.64 (1.30–2.68)

Ref.(0.51–4.94)

0

0

Nutritional Phases Groups

Phase 1a (n = 49)

15.11 ± 3.34 (8.58–23.81)

3.01 ± 1.70 (0.23–7.38)

15(31.9%)

15(30.6%)

Phase 1b (n = 25)

14.89 ± 3.58 (9.19–23.01)

3.09 ± 2.50 (0.02–9.44)

12(25.5%)

12(48.0%)

Phase 2a (n = 23)

16.67 ± 2.38 (13.56–19.89)

2.41 ± 0.70(1.23–4.22)

10(21.3%)

10(43.5%)

Phase 2b (n = 17)

16.51 ± 2.96 (12.94–21.57)

2.63 ± 0.97 (1.24–4.17)

7(14.9%)

7(41.2%)

Phase 3 (n = 16)

17.14 ± 4.35 (11.28–27.61)

2.31 ± 1.12 (0.96–4.54)

3(6.4%)

3(18.8%)

Genotype

Deletion (n = 84)

15.35 ± 3.15 (8.58–23.96)

2.80 ± 1.62(0.02–8.39)

31(66.0%)

31(36.9%)

UPD (n = 33)

16.29 ± 3.75 (11.28–27.61)

2.71 ± 1.35 (0.76–6.99)

13(27.7%)

13(39.4%)

Unclassified (n = 10)

16.59 ± 3.67 (11.84–23.01)

2.16 ± 1.49 (0.41–5.84)

3(6.4%)

3(30.0%)

IC defect (n = 2)

20.93 ± 3.42 (18.51–23.35)

2.89 ± 0.30 (2.68–3.10)

0

0

RT (n = 1)

15.74

9.44

0

0

rhGH therapy

Yes (n = 73)

14.73 ± 2.80 (8.58–23.01)

2.79 ± 1.72 (0.02–8.39)

35(74.5%)

35(47.9%)c

No (n = 57)

17.12 ± 3.64 (9.12–27.61)

2.77 ± 1.54 (0.23–9.44)

12(25.5%)

12(22.6%)

Total (n = 130)

15.77 ± 3.40 (8.58–27.61)

2.78 ± 1.64 (0.02–9.44)

47(100%)

47(36.2%)

  1. Data were recorded as mean ± SD (minimum–maximum) with or withoutreference range. Data of C-HT in the subgroup are presented as a number of patients and percentages according to the patients' group
  2. C-HT Central hypothyroidism, UPD Uniparental disomy, IC Imprinting center, RT Robesonian translocation, rhGH Recombinant human growth hormone, m months, y year, n number, Ref. Reference range
  3. aPercent of patients according to total C-HT (column)
  4. bPercent of patients according to age group (row)
  5. cIn rhGH therapy group, 35 patients (35/73, 47.9%) were identified as C-HT, while 26 of them (26/73, 35.6%) were identified before rhGH treatment, 9 (9/73, 12.3%) were identified during rhGH therapy
Back to article page

BMC Pediatrics

ISSN: 1471-2431

Contact us